Published in Stem Cells on April 01, 2010
Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One (2010) 2.15
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One (2013) 1.45
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther (2010) 1.34
Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res (2010) 1.26
Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol (2013) 1.15
Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis (2011) 1.05
Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther (2011) 1.02
CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med (2012) 1.00
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids (2011) 0.98
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One (2012) 0.96
Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer (2010) 0.96
Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. Int J Oncol (2012) 0.95
Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BMC Cancer (2014) 0.94
NCI-60 whole exome sequencing and pharmacological CellMiner analyses. PLoS One (2014) 0.93
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet (2014) 0.89
Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. BMC Cancer (2015) 0.88
Nonlinear growth kinetics of breast cancer stem cells: implications for cancer stem cell targeted therapy. Sci Rep (2013) 0.87
Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells. BMC Cancer (2015) 0.86
Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013) 0.85
Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma. PLoS One (2012) 0.85
Application of Collagen-Model Triple-Helical Peptide-Amphiphiles for CD44-Targeted Drug Delivery Systems. J Drug Deliv (2012) 0.82
Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. PLoS One (2014) 0.81
The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. J Cell Biochem (2015) 0.81
ALCAM: Basis Sequence: Mouse. AFCS Nat Mol Pages (2015) 0.81
Asymmetric segregation of template DNA strands in basal-like human breast cancer cell lines. Mol Cancer (2013) 0.80
CD24+/CD38- as new prognostic marker for non-small cell lung cancer. Multidiscip Respir Med (2013) 0.79
Cancer stem cells: a systems biology view of their role in prognosis and therapy. Anticancer Drugs (2014) 0.79
Differential expression of neurogenes among breast cancer subtypes identifies high risk patients. Oncotarget (2016) 0.78
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene (2016) 0.77
Initiate Tumors with Single Cell Spheres Formed in Serum-Containing Medium. J Cancer (2015) 0.77
A High Throughput Micro-Chamber Array Device for Single Cell Clonal Cultivation and Tumor Heterogeneity Analysis. Sci Rep (2015) 0.76
Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors. Adv Healthc Mater (2016) 0.75
Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients. BMC Clin Pathol (2015) 0.75
Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer. Chin Med J (Engl) (2016) 0.75
Blockade of Rho-associated protein kinase (ROCK) inhibits the contractility and invasion potential of cancer stem like cells. Oncotarget (2017) 0.75
Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. Breast Cancer Res (2017) 0.75
Transcriptional hallmarks of cancer cell lines reveal an emerging role of branched chain amino acid catabolism. Sci Rep (2017) 0.75
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res (2002) 2.97
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res (2005) 2.49
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Five strategies for accelerating the war on cancer in an era of budget deficits. Oncologist (2009) 2.21
Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst (2011) 2.11
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res (2008) 2.01
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Designing phase 0 cancer clinical trials. Clin Cancer Res (2008) 1.85
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood (2005) 1.74
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res (2008) 1.70
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res (2004) 1.70
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv (2007) 1.64
TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci (2012) 1.60
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci U S A (2011) 1.45
Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem (2002) 1.43
Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther (2007) 1.42
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res (2010) 1.35
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer (2009) 1.32
Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One (2010) 1.31
Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J Med Chem (2006) 1.29
Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model. J Med Chem (2002) 1.21
Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer (2009) 1.20
Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res (2008) 1.20
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res (2004) 1.19
Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res (2008) 1.18
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res (2007) 1.17
Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res (2006) 1.17
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med (2004) 1.15
Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther (2006) 1.14
Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. J Biol Chem (2007) 1.14
Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res (2009) 1.12
New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues. J Med Chem (2008) 1.12
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther (2004) 1.12
Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther (2009) 1.11
Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res (2008) 1.10
Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer (2002) 1.10
A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. Anal Biochem (2005) 1.09
Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem (2002) 1.05
Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS One (2011) 1.04
Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. Cancer Res (2006) 1.03
Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia (2011) 1.02
Phase 0 clinical trials: conceptions and misconceptions. Cancer J (2008) 1.01
Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. Clin Cancer Res (2004) 1.00
Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle (2006) 0.99
Cryoablation and liver resection for noncolorectal liver metastases. Am J Surg (2002) 0.99
Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J Pharmacol Exp Ther (2006) 0.98
Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide. J Natl Cancer Inst (2008) 0.98
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One (2012) 0.96
Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J (2006) 0.96
Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J Virol (2005) 0.96
Should suspected early gallbladder cancer be treated laparoscopically? J Gastrointest Surg (2002) 0.96
Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle (2004) 0.96
Expanding the phenotypic spectrum in EP300-related Rubinstein-Taybi syndrome. Am J Med Genet A (2015) 0.95
Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity. Biochem Biophys Res Commun (2002) 0.95
A novel antimicrobial indolizinium alkaloid from Aniba panurensis. J Nat Prod (2004) 0.95
Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa. J Nat Prod (2009) 0.95
Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. Bioorg Med Chem (2006) 0.95
Aspirochlorine class compounds from Aspergillus flavus inhibit azole-resistant Candida albicans. J Nat Prod (2005) 0.94
Potential for therapeutic targeting of tumor stem cells. Cancer Sci (2009) 0.94
Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle (2009) 0.93
DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs (2002) 0.93
An old problem that may be getting worse. Ann Surg (2008) 0.92
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol (2009) 0.92
Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors. Planta Med (2007) 0.92
Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-γ and lipopolysaccharide in human pancreatic cancer cell lines. J Immunol (2013) 0.91
Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci (2009) 0.91
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin. Int J Cancer (2011) 0.91
A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal Biochem (2003) 0.91
Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach. Antiviral Res (2008) 0.91
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. PLoS One (2012) 0.89
Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother (2005) 0.89
Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J Med Chem (2006) 0.88
Combined serous microcystic adenoma and well-differentiated endocrine pancreatic neoplasm: a case report and review of the literature. Arch Pathol Lab Med (2003) 0.88
DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther (2011) 0.87
Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem Pharmacol (2006) 0.87